Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German HTA Assessment Knocks Back Gilenya In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

IQWiG’s failure to find any added benefit from Novartis’ oral MS drug Gilenya in two out of three of its target patient groups, on the grounds of insufficient evidence, puts pressure on the drug following a similarly negative recommendation by U.K. cost-watchdog NICE at the end of 2011.

Advertisement

Related Content

EMA Passes GSK’s Mekinist, Extends Indications For Gilenya And Pradaxa
Sanofi’s Aubagio And Biogen Idec’s Tecfidera Make It A Good Day For MS Sufferers At EMA
Germany’s Pricing Revolution: Why The World Should Be Watching
Biosimilars Guidance On Interferon Beta From EMA Foreshadows Possible Joint EU/U.S. Approach
Revelations And Resolutions, In Brief
NICE Announces Second Strike Against Gilenya For Cost-Effectiveness
Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint
Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
Novartis' Gilenya Shines Amid Bleak Day for MS Drugs In Europe

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel